These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 372845)

  • 1. [A new therapy of hepatic insufficiency. Experiments with (+)-3--cyanidanol. Its importance in the treatment of alcoholic hepatitis].
    Traissac FJ; Borg R
    Minerva Dietol Gastroenterol; 1977; 23(3):237-42. PubMed ID: 372845
    [No Abstract]   [Full Text] [Related]  

  • 2. [Clinical study of the effect of the administration of cathergen preparation in patients with chronic hepatic lesions].
    Maleev A; Tsvetkova V; Krŭstev Z; Kostova N; Lukanov L
    Vutr Boles; 1985; 24(5):39-43. PubMed ID: 4090451
    [No Abstract]   [Full Text] [Related]  

  • 3. Therapeutic effect of (+)-cyanidanol-3 in toxic alcoholic liver disease and in chronic active hepatitis.
    Abonyi M; Kisfaludy S; Szalay F
    Acta Physiol Hung; 1984; 64(3-4):455-60. PubMed ID: 6397971
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Treatment of chronic diseases of the liver with catergen].
    Loginov AS; Dzhalalov KD; Blok IuE; Bendikov EA; Ausheva LKh
    Ter Arkh; 1986; 58(2):73-6. PubMed ID: 3704945
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Experiments with a new drug in chronic liver diseases, especially alcohol-induced].
    Bel A; Chambon A
    Minerva Dietol Gastroenterol; 1977; 23(3):243-8. PubMed ID: 372846
    [No Abstract]   [Full Text] [Related]  

  • 6. [Study of therapy in chronic liver diseases. Double-blind study with cianidanol].
    Machalke K; Müller B
    Fortschr Med; 1982 Apr; 100(14):665-7. PubMed ID: 6123478
    [No Abstract]   [Full Text] [Related]  

  • 7. [Effect of (+)-cyanidanol-3 in the treatment of chronic active hepatitis (author's transl)].
    Demeulenaere F; Desmet VJ; Dupont E; Fiasse R; Gisselbrecht H; Heully F; Jeanpierre R; Lecomte J; Lennes G; Macinot C; Migeotte P; Pirotte J; Rauber G; Ruyters L; Van Cauwenberge H
    Gastroenterol Clin Biol; 1981 Mar; 5(3):314-23. PubMed ID: 7014344
    [No Abstract]   [Full Text] [Related]  

  • 8. Inhibition of hepatic drug metabolism by (+)-cyanidanol-3 (Catergen) in chronic alcoholic liver disease.
    Pár A; Horváth T; Beró T; Kádas I; Pakodi F; Jávor T
    Acta Physiol Hung; 1984; 64(3-4):449-54. PubMed ID: 6152369
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [A double-blind clinical study of the effect of a new molecule (+)-cyanidanol-3 on the course of the clinical symptoms and biological parameters of viral hepatitis].
    Cachin M; Dupuy R; Boutelier D; Levy C
    Minerva Dietol Gastroenterol; 1977; 23(4):307-12. PubMed ID: 349422
    [No Abstract]   [Full Text] [Related]  

  • 10. (+)-cyanidanol-3.
    Lancet; 1982 Mar; 1(8271):549. PubMed ID: 6120400
    [No Abstract]   [Full Text] [Related]  

  • 11. [What is certain in the therapy of hepatocellular diseases with cyanidanol?].
    Schomerus H
    Internist (Berl); 1983 Dec; 24(12):684-9. PubMed ID: 6363332
    [No Abstract]   [Full Text] [Related]  

  • 12. Effects of (+)-cyanidanol-3 on chronic liver injury.
    Kovách G; Salamon F
    Acta Physiol Hung; 1984; 64(3-4):443-8. PubMed ID: 6152368
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of Catergen [(+)cyanidanol-3] on some haemostatic parameters in chronic liver diseases.
    Pfliegler G; Boda Z; Dalmi L; Weisz G; Misz M; Beck P
    Ther Hung; 1984; 32(1):19-25. PubMed ID: 6571189
    [No Abstract]   [Full Text] [Related]  

  • 14. Clinical, enzymological and histological changes in chronic diffuse liver diseases following (+)-cyanidanol-3 (Catergen) treatment.
    Halmy L; Dávid K; Nagy I; Stotz G; Kelemen JT
    Acta Physiol Hung; 1984; 64(3-4):461-70. PubMed ID: 6152370
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Use of "Essenciale" in the treatment of liver diseases].
    Pogromov AP; Ol'binskaia LI; Antonenko NI; Gitel' NP; Smolianitskiĭ AIa
    Klin Med (Mosk); 1978 Oct; 56(10):97-101. PubMed ID: 362064
    [No Abstract]   [Full Text] [Related]  

  • 16. [The treatment of acute viral hepatitis with (+)-cyanidanol-3].
    Pelloni S; Berthet P; Blum AL; Doelle W; Goebell H; Kortüm K; Peter P; Poulsen H; Strohmeyer G; Tygstrup N
    Schweiz Med Wochenschr; 1977 Dec; 107(49):1859-61. PubMed ID: 337476
    [No Abstract]   [Full Text] [Related]  

  • 17. [Evaluation of therapeutic effect of catergen in viral hepatitis].
    Boroń P; Boroń-Kaczmarska A; Sokolewicz-Bobrowska E; Szpakowicz T; Nadowska K
    Pol Tyg Lek; 1979 Aug; 34(33):1315-7. PubMed ID: 117435
    [No Abstract]   [Full Text] [Related]  

  • 18. (+)-Cyanidanol-3 for alcoholic liver disease: results of a six-month clinical trial.
    World MJ; Aps EJ; Shaw GK; Thomson AD
    Alcohol Alcohol; 1984; 19(1):23-9. PubMed ID: 6149758
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Treatment of chronic hepatitis. A comparative study of the effect azathioprine and (+)-cyanidanol-3].
    Aguilar Reina J; de la Santa López J; Cuadras Avellana CM; Kern A
    Fortschr Med; 1978 Jan; 96(2):75-9. PubMed ID: 74352
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Enzymologic evaluation of the effectiveness of the hepatotropic drug catergen in chronic liver diseases].
    Tamarkina AD; Neverov IV; Turitsyna IG; Dement'eva ES; Krylova NI
    Sov Med; 1985; (12):26-30. PubMed ID: 4095626
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.